MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze To judge multiple intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Main demo aims ended up To judge the protection and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers, even though on the list https://desformylflustrabrominehy34567.digiblogbox.com/56016045/details-fiction-and-qst4